Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Humans and rhesus macaques share maturation pathways of HIV-1 envelope-reactive V3-glycan bnAb lineages.

Science translational medicine·2026

Same author

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026

Same author

Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines.

medRxiv : the preprint server for health sciences·2026

Same author

Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development.

Cell host & microbe·2026

Same author

Systems vaccinology analysis of saRNA immunization identifies an acute innate immune signature correlated with adaptive immunity.

Molecular therapy. Advances·2026

Same author

How Vaccinating People Living With HIV May Guide bNAb‑Based Vaccines.

Journal of the International AIDS Society·2026

Search research articles

Related Experiment Video

Updated: May 15, 2025

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

In danger: HIV vaccine research and development in Europe.

Roger Tatoud¹, Yves Lévy², Roger Le Grand³

¹Origena Consulting, Ferney Voltaire, France.

PLOS Global Public Health

|April 8, 2025

Summary

An HIV vaccine is crucial for ending the epidemic, but research funding is declining. Continued investment in HIV vaccine research and development in Europe is vital for public health and economic benefits.

More Related Videos

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Related Experiment Videos

Last Updated: May 15, 2025

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Area of Science:

Immunology
Epidemiology
Public Health Policy

Background:

Antiretroviral therapy is effective for HIV prevention but faces challenges like unequal access, drug resistance, and treatment barriers.
An effective Human Immunodeficiency Virus (HIV) vaccine remains essential for global epidemic control, complementing existing prevention and treatment strategies.

Purpose of the Study:

To highlight the critical need for continued support of HIV vaccine research and development (R&D) in Europe.
To emphasize the broader benefits of HIV vaccine R&D, including innovation, health security, and economic contributions.

Main Methods:

This is a viewpoint piece, not a research study.
Analysis of the current state of HIV prevention and treatment.
Review of the impact of recent vaccine trial discontinuations and funding trends in Europe.

Main Results:

Discontinuation of major HIV vaccine efficacy studies raises concerns for global and European R&D.
Shrinking funding for HIV vaccine R&D in Europe poses a significant challenge.
Continued investment is essential to overcome these hurdles.

Conclusions:

Supporting HIV vaccine R&D in Europe is crucial for epidemic control.
Investment promotes innovation, enhances epidemic preparedness, and strengthens health sovereignty.
European investment in HIV vaccine R&D offers significant public health and economic advantages.